SCHEMBL3015903

SCHEMBL3015903

Cc1cccc(C)c1-c1csc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3Cl)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 4/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPK1 P28482 2/20 0.46
AR P10275 1/20 0.45
HSD11B1 P28845 1/20 0.45
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TRPV4 Q9HBA0 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 2/20 0.43
RAB9A P51151 1/20 0.42
LPAR1 Q92633 1/20 0.42
LPAR2 Q9HBW0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000574 0.92 ALDH1A1 (0.47) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3009661 0.92 AR (0.45) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3015046 0.90 SMN1; SMN2 (0.55) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3001111 0.90 SMN1; SMN2 (0.46) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3012852 0.89 AR (0.47) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3020756 0.89 AR (0.49) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3001220 0.89 SMN1; SMN2 (0.48) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3011983 0.89 KMT2A (0.54) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3018867 0.88 ALDH1A1 (0.53) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3017917 0.87 MAPT (0.49) MAPTMEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.